請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40798
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 符文美 | |
dc.contributor.author | Peng-Ru Chen | en |
dc.contributor.author | 陳鵬如 | zh_TW |
dc.date.accessioned | 2021-06-14T17:00:47Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-12 | |
dc.identifier.citation | Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-864.
Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Wurl P, Taubert H, Vordermark D (2010) Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10:132. Behera R, Kumar V, Lohite K, Karnik S, Kundu GC (2010) Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 31:192-200. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967-975. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6:819-830. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK (2007) Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:373-380. Chellaiah MA, Hruska KA (2003) The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int 72:197-205. Chen L, Endler A, Shibasaki F (2009) Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp Mol Med 41:849-857. Chen RX, Xia YH, Xue TC, Zhang H, Ye SL (2011) Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 25:803-808. Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH (1999) Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1alpha. J Cell Sci 112 ( Pt 8):1203-1212. Coussens LM, Werb Z (1996) Matrix metalloproteinases and the development of cancer. Chem Biol 3:895-904. D'Abaco GM, Kaye AH (2007) Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14:1041-1048. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-437. Diao H, Liu X, Chen Y, Xu W, Cao H, Kohanawa M, Li L (2011) Osteopontin expression and relation to streptococcal disease severity in mice. Scand J Infect Dis 43:100-106. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-38211. Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sorensen ES, Boskey AL (2005) Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 77:45-54. Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JJ, Niewiarowski S (1990) Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 195:168-171. Gu JL, Ji QH, Wu XM, Jin SY, Zhu L (2007) [Expression of HIF-1alpha induced by ginkgolides in primary cultured cortical nenrons and the relationship with ERK signal pathway]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 23:430-433. Guo H, Wai PY, Mi Z, Gao C, Zhang J, Kuo PC (2008) Osteopontin mediates Stat1 degradation to inhibit iNOS transcription in a cecal ligation and puncture model of sepsis. Surgery 144:182-188. Haddad JJ (2002) Recombinant human interleukin (IL)-1 beta-mediated regulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilization, nuclear translocation and activation requires an antioxidant/reactive oxygen species (ROS)-sensitive mechanism. Eur Cytokine Netw 13:250-260. Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Hofler H, Schmitt M, Reuning U (2003) Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem 384:1073-1083. Hayashi C, Rittling S, Hayata T, Amagasa T, Denhardt D, Ezura Y, Nakashima K, Noda M (2007) Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 101:979-986. Huang TF, Wu YJ, Ouyang C (1987) Characterization of a potent platelet aggregation inhibitor from Agkistrodon rhodostoma snake venom. Biochim Biophys Acta 925:248-257. Hullinger TG, Pan Q, Viswanathan HL, Somerman MJ (2001) TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements. Exp Cell Res 262:69-74. Hwang SM, Wilson PD, Laskin JD, Denhardt DT (1994) Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: contrasting responses to hypoxia and reoxygenation. J Cell Physiol 160:61-68. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687. Jan HJ, Lee CC, Shih YL, Hueng DY, Ma HI, Lai JH, Wei HW, Lee HM (2010) Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 12:58-70. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M (2001) Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 15:1312-1314. Kaomongkolgit R, Manokawinchoke J, Sanchavanakit N, Pavasant P, Sumrejkanchanakij P (2010) Fibronectin supports TNF-alpha-induced osteopontin expression through beta1 integrin and ERK in HN-22 cells. Arch Oral Biol 55:101-107. Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB, Koul HK (2009) Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 28:1248-1260. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J (2004) Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279:9899-9904. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6:1335-1340. Lamour V, Le Mercier M, Lefranc F, Hagedorn M, Javerzat S, Bikfalvi A, Kiss R, Castronovo V, Bellahcene A (2010) Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 126:1797-1805. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY (2007) Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67:2089-2097. Lefranc F, Brotchi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23:2411-2422. Li G, Jin R, Norris RA, Zhang L, Yu S, Wu F, Markwald RR, Nanda A, Conway SJ, Smyth SS, Granger DN (2010) Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis 208:358-365. Li Y, Li L, Wang JT, Kan X, Lu JG (2011) Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol. Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024-46030. Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B (2009) Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A 106:10666-10671. Lynn BD, Turley EA, Nagy JI (2001) Subcellular distribution, calmodulin interaction, and mitochondrial association of the hyaluronan-binding protein RHAMM in rat brain. J Neurosci Res 65:6-16. Mi Z, Guo H, Wai PY, Gao C, Kuo PC (2006) Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27:1134-1145. Mori R, Shaw TJ, Martin P (2008) Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 205:43-51. Nyhan MJ, El Mashad SM, O'Donovan TR, Ahmad S, Collins C, Sweeney P, Rogers E, O'Sullivan GC, McKenna SL (2011) VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin. Cell Oncol (Dordr). O'Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS (1999) Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 162:1024-1031. Oh JM, Ryoo IJ, Yang Y, Kim HS, Yang KH, Moon EY (2008) Hypoxia-inducible transcription factor (HIF)-1 alpha stabilization by actin-sequestering protein, thymosin beta-4 (TB4) in Hela cervical tumor cells. Cancer Lett 264:29-35. Ouyang C, Yeh HI, Huang TF (1983) A potent platelet aggregation inhibitor purified from Agkistrodon halys (mamushi) snake venom. Toxicon 21:797-804. Rangaswami H, Bulbule A, Kundu GC (2004) Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 279:38921-38935. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79-87. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3:489-501. Rezvani HR, Dedieu S, North S, Belloc F, Rossignol R, Letellier T, de Verneuil H, Taieb A, Mazurier F (2007) Hypoxia-inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem 282:16413-16422. Ricardo SD, Franzoni DF, Roesener CD, Crisman JM, Diamond JR (2000) Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells. Am J Physiol Renal Physiol 278:F708-716. Said HM, Hagemann C, Staab A, Stojic J, Kuhnel S, Vince GH, Flentje M, Roosen K, Vordermark D (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83:398-405. Salceda S, Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642-22647. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732. Semenza GL (2009) HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 15:3839-3843. Sharp FR, Bernaudin M (2004) HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 5:437-448. Sheu JR, Lin CH, Chung JL, Teng CM, Huang TF (1992) Triflavin, an Arg-Gly-Asp-containing antiplatelet peptide inhibits cell-substratum adhesion and melanoma cell-induced lung colonization. Jpn J Cancer Res 83:885-893. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23:123-133. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E (2009) Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69:3308-3316. Sodhi CP, Phadke SA, Batlle D, Sahai A (2001) Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Renal Physiol 280:F667-674. Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL (2008) Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci 99:1901-1907. Song G, Ouyang G, Mao Y, Ming Y, Bao S, Hu T (2009) Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med 13:1706-1718. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX (2008) Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 48:1834-1842. Swenson S, Ramu S, Markland FS (2007) Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des 13:2860-2871. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY (2010) Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol 100:217-223. Varner JA, Cheresh DA (1996) Integrins and cancer. Curr Opin Cell Biol 8:724-730. Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103-118. Weintraub AS, Schnapp LM, Lin X, Taubman MB (2000) Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis. Lab Invest 80:1603-1615. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G (2010) Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 28:3316-3322. Wong ML, Kaye AH, Hovens CM (2007) Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14:301-308. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT (2007) Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56:782-789. Yang RS, Chiang HS, Tang CH, Yeh CS, Huang TF (2005) Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of alphavbeta3 integrin. Toxicon 46:387-393. Yang XM, Wang YS, Zhang J, Li Y, Xu JF, Zhu J, Zhao W, Chu DK, Wiedemann P (2009) Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci 50:1873-1879. Yu XQ, Fan JM, Nikolic-Paterson DJ, Yang N, Mu W, Pichler R, Johnson RJ, Atkins RC, Lan HY (1999) IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am J Pathol 154:833-841. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86:1221-1232. Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, Wang L, Zhang BH, Liu YK, Tang ZY, Qin LX (2006) The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132:709-717. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40798 | - |
dc.description.abstract | 人類惡性神經膠瘤,是最常見的原位性腦瘤,其特性是廣泛的浸潤到鄰近的正常腦組織。目前用來治療神經膠瘤的方法包含手術治療、傳統放射治療、或是化學藥物治療,但是都因為這項特徵而使得治療的效果有限。骨調素(osteopontin)是一種磷酸化的醣蛋白,一些癌細胞會過度分泌骨調素,而大量的骨調素與癌症的惡化有關。有文獻指出骨調素參與癌症的進程,例如異常的細胞分裂、細胞遷移、細胞侵入、和血管新生。除此之外,也有文獻指出在缺氧的情況下觀察到骨調素的表現增加。癌細胞在缺氧的情況下會藉由穩定缺氧誘導因子(HIF)來克服缺氧時所面對的壓力。基於以上的觀點,我們探討在神經膠瘤細胞中骨調素對HIF-1α表現的調控作用,並且探討disintegrin (HSA(C34S)-ARLDDL、PEG-ARLDDL)的抑制作用,這些disintegrins是從Rhodostomin中改變RGD domain附近胺基酸序列所獲得的衍生物,對αvβ3有專一性的拮抗作用。在本篇研究結果顯示人類神經膠瘤細胞U87在缺氧的情況下會促進骨調素的表現。外給骨調素會促使在缺氧下累積更多的HIF-1α蛋白,但不影響HIF-1αmRNA的表現,而osteopontin增加蛋白之表現會被disintegrin HSA(C34S)-ARLDDL所拮抗。此外,利用西方點墨法分析核內蛋白及免疫螢光染色證實骨調素會促進HIF-1α蛋白轉移到核內。更進一步發現,外給骨調素可以促進U87在缺氧下分泌更多的VEGF以及更嚴重的細胞侵入(invasion),但是在給予disintegrin PEG-ARLDDL後便會抑制此U87的侵入行為。另外我們轉殖一小段具有專一性拮抗骨調素mRNA的RNA,可使骨調素的表現量下降。骨調素表現缺乏的U87細胞在CoCl2的刺激之下比起正常的U87細胞表現較少的HIF-1α蛋白,利用HRE-luciferase reporter assay也發現此種細胞有較少的HIF-1α轉譯活性。在缺氧的情況下骨調素缺乏的U87細胞比起正常的U87細胞有較少的細胞遷移 (migration)。此外,在骨調素缺乏的U87細胞中給予骨調素會恢復其HIF-1α的表現量,而此現象會被LY294002(PI3K的抑制劑)及SB203580(p38的抑制劑)所拮抗,進一步我們也觀察到外給骨調素會增加這些細胞中Akt、p38及FAK的磷酸化。
總結本篇的研究結果,我們發現在人類神經膠瘤細胞中給予骨調素會促進缺氧下所誘導的HIF-1α蛋白的堆積及細胞的侵入,在給予disintegrin後便可拮抗此作用。此外我們也證實了人類神經膠瘤細胞在缺氧的環境下骨調素與HIF-1α蛋白之間的關係。骨調素可能是藉由integrin、PI3K及p38這些訊息傳遞路徑來調控HIF-1α蛋白的表現。 | zh_TW |
dc.description.abstract | Human malignant gliomas, the most common primary brain tumors, are characterized by their ability to infiltrate to adjacent normal brain tissue. This infiltrative feature causes the limit effectiveness for present therapies including surgery, radiation therapy and chemotherapy. Osteopontin, a phosphorylated glycoprotein, is overexpressed in several cancers and correlates with tumor grade. Previous reports have indicated that osteopontin participates in tumor progression such as proliferation, migration, invasion, and angiogenesis. In addition, elevated osteopontin expression is observed following hypoxia, and tumor cells overcome hypoxia stress by the stabilization of hypoxia inducible factor (HIF) transcriptional regulators.
Based on these viewpoints, we investigated the effect of osteopontin on HIF-1α expression in glioblastoma, and explored the inhibitory effects of two kinds of αvβ3-selective disintegrins (HSA(C34S)-ARLDDL, PEG-ARLDDL) derived from the mutation of RGD neighborhood of Rhodostomin. It was found that the expression of osteopontin increased after exposure to hypoxia in U87 human glioma cells. Exogenous application of osteopontin enhanced hypoxia-induced HIF-1α protein expression, which was attenuated by the co-treatment with disintegrin HSA (C34S)-ARLDDL. Osteopontin at concentration of 3 ng/ml did not affect HIF-1α mRNA expression. In addition, we showed that application of osteopontin facilitated HIF-1α translocation to nucleus using nuclear extract Western blot analysis and also confirmed by the nuclear localization of HIF-1α using immunofluorescent staining. Furthermore, it was found that exogenous osteopontin enhanced hyoxia-induced VEGF secretion and facilitated U87 cell invasion, which was antagonized by the disintegrin of PEG-ARLDDL. We further transfected U87 MG with a specific small hairpin RNA to knockdown osteopontin expression. Osteopontin-deficient U87 MG cells gave rise to less HIF-1α protein than control cells, and less HIF-1α transcriptional activity estimated by HRE-luciferase reporter assay after CoCl2 treatment. Osteopontin knockdown decreased the U87 MG cell migration under hypoxia. Furthermore, application of osteopontin to osteopontin-knockdown cells could reverse the HIF-1α expression, which was attenuated by the treatment of LY294002 (PI3K inhibitor) and SB203580 (p38 inhibitor). Moreover, exogenous osteopontin also increased the phosphorylation level of Akt, p38, and FAK. In conclusion, osteopontin enhanced hypoxia-induced HIF-1α protein accumulation and invasion in human U87 glioma cells. Treatment of disintegrin could antagonize these effects. Moreover, a relationship between osteopontin and HIF-1α in glioblastoma cells under hypoxia treatment was demonstrated. The regulation of osteopontin on HIF-1α protein may act through integrin,PI3K, and p38 signaling pathways. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T17:00:47Z (GMT). No. of bitstreams: 1 ntu-100-R98443008-1.pdf: 2731003 bytes, checksum: 47483af7a5e8ab6f2f8f51b71c457b3c (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | Abbreviations………………………………………………………….V
摘要……………………………………………………………………..VI Abstract…………………………………………………………....VII Chapter 1 Introduction…………………………………………1 1-1 Glioma………………………………………………………1 1-2 Osteopontin………………………………………………..2 1-3 Integrin and disintegrin……………………………..5 1-4 Hypoxia…………………………………………………….7 Chapter 2 Materials and Methods…………………………………15 Chapter 3 Results…………………………………………………….22 3-1. Effect of cobalt chloride on osteopontin protein expression in glioblastoma cell line……………………………22 3-2. Effect of osteopontin on hypoxia- or CoCl2-induced HIF-1α protein expression……………23 3-3. αvβ3 integrin is involved in osteopontin–induced HIF-1α expression.23 3-4. Effect of osteopontin on CoCl2-induced HIF-1α nuclear translocation25 3-5. Effect of osteopontin on hypoxia-induced VEGF secretion………25 3-6. Effect of osteopontin on hypoxia-induced invasion of glioblastoma cells……………………………………………………26 3-7. Effect of endogenous osteopontin on CoCl2-induced HIF-1α protein expression……………………………………27 3-8. Effect of endogenous osteopontin on CoCl2-induced HRE-luciferase activity……………………………………………....27 3-9. Osteopontin knockdown inhibits U87 cell migration……28 3-10. Osteopontin increases HIF-1α protein expression in osteopontin knockdown cells…………………………………28 3-11. Involvement of PI3k/AKt and p38 MAPK in osteopontin –induced HIF-1α protein expression………………………………29 Chapter 4 Discussion and Conclusion……………………..……31 References…………………………………………………………….51 圖目錄 Figure 1-3-1. Integrin subunit heterodimerization......................................11 Figure 1-3-2. Integrin signaling…………………………………12 Figure 1-4-1. O2-dependent regulation of HIF-1α activity…………………..13 Figure 1-4-2. Genes involved in tumor progression are upregulated by HIF-1α………………………………14 Figure 3-1. Expression of osteopontin is up-regulated by CoCl2 in U87 cells.37 Figure 3-2. Osteopontin enhances hypoxia- or CoCl2-induced HIF-1α protein expression in U87 cells………………………38 Figure 3-3. Inhibition by αvβ3 integrin antagonist on osteopontin-enhanced HIF-1α protein expression under hypoxia……………..………39 Figure 3-4. Treatment of recombinant osteopontin increases CoCl2-induced HIF-1α nuclear translocation…………………40 Figure 3-5. Osteopontin enhances CoCl2-induced HIF-1α nuclear translocation by immunofluorescent staining………41 Figure 3-6. Osteopontin enhances hypoxia-induced VEGF secretion in U87 cells……………………………………42 Figure 3-7. Osteopontin potentiates U87 invasion in a αvβ3-dependent manner………………………43 Figure 3-8. Knockdown of osteopontin inhibits CoCl2-induced HIF-1α accumulation in U87 cells…………………….44 Figure 3-9. Endogenous osteopontin is involved in CoCl2–induced HIF-1α expression…………………………45 Figure 3-10. Osteopontin knockdown reduces cell migration of U87 glioma cells………………………………46 Figure 3-11. Increase of CoCl¬2-induced HIF-1α protein expression by osteopontin in osteopontin-knockdown cells………..…….…47 Figure 3-12. PI3K/Akt and p38 MAPK signaling pathways are involved in osteopontin-mediated HIF-1α accumulation in U87 cells…..…48 Figure 3-13. Exogenous osteopontin stimulates phosphorylation of Akt, p38, and FAK in U87 cells……………………………………..…49 Figure 3-14. Integrin, PI3K/Akt and p38 signaling pathways are involved in osteopontin-enhanced HIF-1α accumulation under hypoxia in U87 cells……………………………………………….......50 | |
dc.language.iso | en | |
dc.title | 探討osteopontin在神經膠瘤細胞對HIF-1α的調節作用 | zh_TW |
dc.title | Regulation of HIF-1α by osteopontin in glioblastoma cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊春茂,劉宏輝,林琬琬,李銘仁 | |
dc.subject.keyword | 骨調素,缺氧,神經膠瘤,組合蛋白,去組合蛋白, | zh_TW |
dc.subject.keyword | osteopontin,hypoxia,glioma,integrin,disintegrin, | en |
dc.relation.page | 57 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 2.67 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。